Page 2 - Preclinical Data News Today

OXFORD, England, October 16, 2023--Exscientia plc (Nasdaq: EXAI) today announced two abstracts to be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain.

Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disordersBOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin agonist development candidat...

Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meeting in Portugal Data provides further evidence that selective neuronal nitric oxide synthase (nNOS) inhibitors can play a role in the treatment of ASD Poster presentation position nitric oxide (NO) as a novel therapeutic target for ASD: Focus on CNTNAP2-/- mouse model GARDEN CITY, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyon...

BOSTON, August 03, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries.

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual... | June 9, 2023

Latest news on Seismology, the study of earthquakes and seismic waves that move through and around the Earth.

Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the... | May 18, 2023

Expands pipeline with acquisition of new tri-specific antibodiesData readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple

- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 - - First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and... | May 11, 2023

Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023